FGFR3 and inclusion body myositis: Moreover, the recent discovery of new autoantibodies (such as anti-nodal and paranodal antibodies in auto-immune nodopathies, anti-FGFR3 and AGO1 in sensory neuronopathies or anti-cN1a in inclusion-body myositis) has led to a better understanding of the pathophysiology of immune-mediated neuromuscular diseases.